Form 4: Assembly Biosciences Director Gina Consylman Granted 3,500 Stock Options

Assembly Biosciences, Inc. director Gina Consylman was granted 3,500 stock options with an exercise price of $15.81, vesting by June 2026 or the 2026 annual meeting.

Summary

• Gina Consylman, a Director of Assembly Biosciences, Inc. (ASMB), was granted 3,500 stock options.
• The options have an exercise price of $15.81 per share.
• These options are for the right to buy 3,500 shares of Common Stock.
• The options vest upon the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, contingent on continuous service.
• The options expire on June 5, 2035.

Sentiment

Score: 7

Explanation: The filing is a routine Form 4 indicating a standard equity grant to a director, which is generally a positive sign of continued alignment and compensation, with no negative implications.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance.
• This is a routine compensation event for a director, indicating stable corporate governance practices.

Negatives

• No negative information is present in this Form 4 filing.

Risks

• The value of the stock options is dependent on the future performance of Assembly Biosciences' stock price. If the stock price does not exceed the exercise price of $15.81, the options may not be in-the-money.
• Vesting is contingent on continuous service, meaning the director must remain with the company until the vesting date to realize the benefit.

Future Outlook

The stock options are forward-looking instruments designed to incentivize the director's long-term commitment and performance, with vesting scheduled for June 5, 2026, or the 2026 annual meeting, and an expiration date of June 5, 2035.

Management Comments

• The filing was signed by John O. Gunderson, as Attorney-in-Fact for Gina Consylman.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like Assembly Biosciences, to align the interests of board members with those of shareholders and to attract and retain qualified talent. This type of equity compensation is a standard component of director remuneration packages.

Comparison to Industry Standards

• The grant of stock options to directors is a standard practice across publicly traded companies, particularly in the biotech sector, where long-term value creation is paramount.
• While specific comparable companies (e.g., Gilead Sciences, Vertex Pharmaceuticals, Moderna) would have varying grant sizes based on company size, director roles, and compensation philosophies, the mechanism of granting options with a vesting schedule and an exercise price is consistent with industry benchmarks.
• The exercise price of $15.81 is the market price at the time of grant, which is typical for incentive stock options.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director, Gina Consylman, can be considered a related party transaction as it involves compensation to an insider. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance. It also represents a potential future dilution if options are exercised, though this is a standard part of equity compensation plans.
• Employees: No direct impact on general employees is noted.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is noted.

Next Steps

• The stock options will vest upon the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, assuming continuous service.
• The director may choose to exercise the options at any time after vesting and before the expiration date of June 5, 2035, provided the stock price is above the exercise price.

Key Dates

Keywords

Assembly Biosciences, ASMB, Form 4, SEC filing, stock options, director compensation, equity grant, insider transaction, Gina Consylman